Publicaciones en colaboración con investigadores/as de Charles University in Prague (9)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  3. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

    Blood, Vol. 141, Núm. 6, pp. 579-591

2018

  1. Cancertool: A visualization and representation interface to exploit cancer datasets

    Cancer Research, Vol. 78, Núm. 21, pp. 6320-6328

2015

  1. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

2014

  1. A benchmark for comparison of cell tracking algorithms

    Bioinformatics, Vol. 30, Núm. 11, pp. 1609-1617

2013

  1. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

1995

  1. Identical intragenic microsatellite haplotype found in cystic fibrosis chromosomes bearing mutation G551D in Irish, English, Scottish, Breton and Czech Patients

    Human Heredity, Vol. 45, Núm. 1, pp. 6-12